The Section of Vascular Surgery, directed by Luis Sanchez, M.D., oversees the vascular diagnostic laboratory at Barnes-Jewish Hospital and also is responsible for the Vascular Surgery service.
Gregorio Sicard, M.D., Brian Rubin, M.D., and Luis A. Sanchez, M.D., lead an active endovascular program for the treatment of aneurysmal and occlusive vascular disease. This team currently is participating in multiple trials of minimally invasive (endoluminal) treatment of vascular disease.
Robert W. Thompson, M.D. has been a pioneer and published extensively regarding the activity of metalloproteases and inflammation on the pathobiology of abdominal aortic aneurysms. He continues to actively collaborate in this area of investigation, and is the acting clinical site PI for the N-TA3CT study (Non-invasive Treatment of Abdominal Aortic Aneurysms Clinical Trial). He is also leveraging one of the world’s largest experiences in Thoracic Outlet Syndromes to explore the optimization of clinical management. He is developing extensive databases of patient data and therapeutic outcomes, and has multiple publications describing operative techniques and patient outcomes. He is recognized as a leader in education of surgeon-scientists, and has personally served as research mentor for a number of surgeons that have developed independent careers in research.
John A. Curci, M.D., has a very active NIH-supported research laboratory that focuses on the discovery and translation of the basic mechanisms of abdominal aortic aneurysm (AAA) formation and growth. There are several major active areas of interest that span basic science to translational areas. The lab has expertise in molecular biology, immunology, proteomics, tissue culture and surgical small animal models of disease. The lab currently serves as the Biomarkers Core Laboratory for N-TA3CT, a national multi-center, double-blind, placebo controlled study to determine the effect of metalloprotease inhibition on the growth of small aortic aneurysms. Dr. Curci is also one of the national principal investigators of the trial. More basic investigation into the pathology of AAA includes the study of the mechanisms of the specific vascular degenerative effects of tobacco smoke on the development of AAA in murine models. The lab is also working to develop a mechanistic understanding of the unique biology of the smooth muscle cells grown from the aneurysm tissue. The lab has an excellent track record of successful projects by medical students, residents and fellows, with work by our trainees resulting in national and international research awards.
Patrick J. Geraghty, M.D. is actively involved at the national level in endovascular outcomes research, with a primary focus on peripheral arterial disease and popliteal aneurysms. He serves on the SVS Outcomes Committee, SVS Critical Limb ischemia Workgroup, and SVS Lower Extremity Practice Guidelines Writing Group. These committee efforts, and his participation in the Peripheral Academic Research Consortium, lead to frequent advisory roles with the FDA and various industry groups. He has served as national co-principal investigator for the VIBRANT trial of SFA intervention, and is the national PI for the upcoming FORMAT trial of iliac stenting. With other members of the Washington University Medical School vascular surgery and acute care surgical sections, he has worked to create the first multidisciplinary limb preservation center in the greater St. Louis area. Other current research areas involve the use of G-CSF stimulation for critical limb ischemia patients who have exhausted their revascularization options, and ongoing evaluation of outcomes of covered stenting for popliteal aneurysm treatment.